首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1471981

經黏膜給藥系統市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按系統、最終用戶和地理位置

Transmucosal Drug Delivery Systems Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By System, End User, and Geography

出版日期: 2024年03月21日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

經黏膜給藥系統市場價值2023年為802.1億美元，到2031年將達到1,294.6億美元；預計2023年至2031年複合年成長率為6.2%。

推動市場成長的關鍵因素是疾病管理中藥物輸送系統的持續採用，推動了跨黏膜藥物輸送系統市場的成長。此外，新藥物分子和生物製劑的開發也有助於市場成長。然而，與生物相容性和有限的候選藥物相關的擔憂阻礙了市場的成長。

經黏膜給藥系統市場的市場趨勢：

將奈米技術整合到跨黏膜藥物遞送系統中，可以設計奈米級藥物載體，從而增強藥物的理化性質並靶向遞送至黏膜組織。已經提出了幾種將含藥物奈米粒子（NP）加載到頰粘膜上以進行局部和全身應用的策略。人們對開發黏膜黏附頰配方特別是包含含有奈米粒子的黏膜黏附膜的水凝膠複合材料產生了濃厚的興趣。例如，多學科數位出版研究所 (MDPI) 於 2020 年 8 月發表的一篇評論文章討論了二氧化矽奈米粒子在跨黏膜藥物輸送中的各種應用。該文章的結論是，二氧化矽奈米顆粒已顯示出作為跨黏膜藥物遞送的有效藥物奈米載體的前景。這是因為它們可以使用簡單的方法輕鬆製備，並提供對顆粒大小和形狀的控制、高載藥量和受控的藥物輸送。透過合成具有不同官能基的不同類型的二氧化矽奈米顆粒，可以實現更好的藥物遞送功效。

因此，藥物輸送系統的此類技術進步預計將在未來幾年帶來新的市場趨勢。

經黏膜給藥系統市場：細分概述

經黏膜給藥系統市場根據系統和最終用戶進行細分。

依系統分類，市場分為鼻肺、口腔和舌下、陰道等。鼻肺部分在 2023 年佔據最大的經黏膜給藥系統市場佔有率，預計 2023-2031 年複合年成長率最高。頰部給藥途徑是一種非侵入性局部方法，其中藥物被保留或施用於頰腔中，即臉頰和牙齦之間的空間。藥物經由口腔黏膜吸收後，經由頸靜脈繞過腸道進入體循環。這種給藥方式具有許多優點，例如起效快、生物利用度高於口服途徑。這種方法還可以避免首過代謝，從而保護其免於在胃腸道中分解。

就最終用戶而言，經黏膜給藥系統市場分為醫療機構、家庭護理機構等。 2023 年，醫療保健設施領域佔據最大的市場佔有率。家庭護理設置領域預計在 2023 年至 2031 年期間複合年成長率最高。

經黏膜給藥系統市場：地理概況

經黏膜給藥系統市場報告的範圍涉及北美（美國、加拿大和墨西哥）、歐洲（西班牙、英國、德國、法國、義大利和歐洲其他地區）、亞太地區（韓國、中國）、印度、日本、澳洲和亞太其他地區）、中東和非洲（南非、沙烏地阿拉伯、阿拉伯聯合大公國以及中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲其他地區）。就收入而言，2023年北美將佔據最大的經黏膜給藥系統市場佔有率。這可以歸因於糖尿病、氣喘和心臟病等慢性病病例的增加，以及主要參與者推出的產品數量的增加。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 10 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 11 章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 12 章：經黏膜給藥系統市場 - 主要公司概況

Teva Pharmaceutical Industries Ltd
Cigna Corporation
BioDelivery Sciences International, Inc
3M
Henkel Finland Oy
GlaxoSmithKline plc
Aquestive Therapeutics, Inc
Camurus AB
Ximedica
Noven Pharmaceuticals, Inc

第 13 章：附錄

簡介目錄

Product Code: TIPRE00004209

The transmucosal drug delivery systems market was valued at US$ 80.21 billion in 2023 to US$ 129.46 billion by 2031; it is estimated to register a CAGR of 6.2% from 2023 to 2031.

Key factors driving the market growth are the rising adoption of drug delivery systems for disease management propels the transmucosal drug delivery systems market growth. Additionally, the development of new drug molecules and biological formulations is contributing to market growth. However, the concerns associated with biocompatibility and limited drug candidates hamper the market growth.

Market Trends of the Transmucosal Drug Delivery Systems Market:

Integration of nanotechnology into transmucosal drug delivery systems enables the design of nanoscale drug carriers that can enhance the physicochemical properties of the drug and target delivery to the mucosal tissues. Several strategies have been suggested for loading drug-containing nanoparticles (NPs) onto the buccal mucosa for local and systemic applications. There has been significant interest in developing mucoadhesive buccal formulations, particularly hydrogel composites that incorporate mucoadhesive films containing NPs. For instance, a review article published by the Multidisciplinary Digital Publishing Institute (MDPI) in August 2020 discussed various applications of silica NPs in transmucosal drug delivery. The article concluded that silica nanoparticles have shown promise as effective drug nanocarriers for transmucosal drug delivery. This is because they can be easily prepared using simple methods and offer control over particle size and shape, high drug loading capacity, and controlled drug delivery. By synthesizing different types of silica NPs with various functional groups, it is possible to achieve even greater drug delivery efficacy.

Therefore, such technological advancements in the drug delivery systems are expected to bring new market trends in the coming years.

Transmucosal Drug Delivery Systems Market: Segmental Overview

The transmucosal drug delivery systems market is segmented on the basis of systems and end user.

By systems, the market is segmented into nasopulmonary, buccal & sublingual, vaginal, and others. The nasopulmonary segment held the largest transmucosal drug delivery systems market share in 2023 and is anticipated to register the highest CAGR during 2023-2031. The buccal route of drug administration is a noninvasive, topical method in which drugs are held or applied in the buccal cavity, i.e., the space between the cheek and gums. After their absorption through the oral mucosa, drugs enter the systemic circulation through the jugular vein, bypassing the intestines. This drug administration has many advantages, such as rapid onset of action and a higher bioavailability than the oral route. This method also evades first-pass metabolism, which protects it from degradation in the gastrointestinal (GI) tract.

In terms of end user, the transmucosal drug delivery systems market is segmented into healthcare facilities, homecare settings, and others. The healthcare facilities segment held the largest market share in 2023. The market growth of this segment can be attributed to the availability of better facilities and skilled physicians in hospitals. The homecare settings segment is anticipated to register the highest CAGR during 2023-2031.

Transmucosal Drug Delivery Systems Market: Geographical Overview

The scope of the transmucosal drug delivery systems market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). In terms of revenue, North America held the largest transmucosal drug delivery systems market share in 2023. The US dominates the market in this region. This can be attributed to the increasing cases of chronic diseases such as diabetes, asthma, and cardiac diseases as well as the growing number of product launches by key players.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Transmucosal Drug Delivery Systems Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Transmucosal Drug Delivery Systems Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Transmucosal Drug Delivery Systems Market - Global Market Analysis

6.1 Transmucosal Drug Delivery Systems - Global Market Overview
6.2 Transmucosal Drug Delivery Systems - Global Market and Forecast to 2031

7. Transmucosal Drug Delivery Systems Market - Revenue Analysis (USD Million) - By System, 2021-2031

7.1 Overview
7.2 Nasopulmonary
7.3 Buccal and Sublingual
7.4 Vaginal
7.5 Others

8. Transmucosal Drug Delivery Systems Market - Revenue Analysis (USD Million) - By End User, 2021-2031

8.1 Overview
8.2 Healthcare Facilities
8.3 Homecare settings
8.4 Others

9. Transmucosal Drug Delivery Systems Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

9.1 North America
- 9.1.1 North America Transmucosal Drug Delivery Systems Market Overview
- 9.1.2 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts to 2031
- 9.1.3 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts and Analysis - By System
- 9.1.4 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts and Analysis - By End User
- 9.1.5 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Countries
  - 9.1.5.1 United States Transmucosal Drug Delivery Systems Market
    - 9.1.5.1.1 United States Transmucosal Drug Delivery Systems Market, by System
    - 9.1.5.1.2 United States Transmucosal Drug Delivery Systems Market, by End User
  - 9.1.5.2 Canada Transmucosal Drug Delivery Systems Market
    - 9.1.5.2.1 Canada Transmucosal Drug Delivery Systems Market, by System
    - 9.1.5.2.2 Canada Transmucosal Drug Delivery Systems Market, by End User
  - 9.1.5.3 Mexico Transmucosal Drug Delivery Systems Market
    - 9.1.5.3.1 Mexico Transmucosal Drug Delivery Systems Market, by System
    - 9.1.5.3.2 Mexico Transmucosal Drug Delivery Systems Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

9.2 Europe
- 9.2.1 Germany
- 9.2.2 France
- 9.2.3 Italy
- 9.2.4 Spain
- 9.2.5 United Kingdom
- 9.2.6 Rest of Europe
9.3 Asia-Pacific
- 9.3.1 Australia
- 9.3.2 China
- 9.3.3 India
- 9.3.4 Japan
- 9.3.5 South Korea
- 9.3.6 Rest of Asia-Pacific
9.4 Middle East and Africa
- 9.4.1 South Africa
- 9.4.2 Saudi Arabia
- 9.4.3 U.A.E
- 9.4.4 Rest of Middle East and Africa
9.5 South and Central America
- 9.5.1 Brazil
- 9.5.2 Argentina
- 9.5.3 Rest of South and Central America

10. Industry Landscape

10.1 Mergers and Acquisitions
10.2 Agreements, Collaborations, Joint Ventures
10.3 New Product Launches
10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration

12. Transmucosal Drug Delivery Systems Market - Key Company Profiles

12.1 Teva Pharmaceutical Industries Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies